Many retrospective studies in colon and lung cancers have demonstrated poor clinical outcomes as a result of treatment with EGFR tyrosine kinase inhibitors in patients harbouring KRAS mutations [74,75,76,77,78]. Here, KRAS is linked to lung cancer.